Menlo Therapeutics (MNLO) Plans Offering of Common Stock

Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the common stock to be sold in the offering will be offered by Menlo. In addition, Menlo expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Cowen and Piper Sandler & Co. are acting as joint book-runners for the proposed offering. LifeSci Capital LLC is acting as lead manager.

A shelf registration statement relating to these securities was previously filed with the Securities and Exchange Commission (“SEC”) and declared effective on February 12, 2019.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Autonomix Medical raises $2.6M via warrant inducement agreement
• Jones Ventures INTL Acquisition1 prices $200M IPO on Nasdaq